All Stories

  1. Hericenone C exhibits anti-nociceptive effects through RORα-mediated suppression of TLR4 transcription
  2. Gas Chromatography–Mass Spectroscopy ( GC – MS ) Simultaneous Determination of Limonene, Linalool, and Linalyl Acetate in Rat Plasma Following Transde...
  3. Metformin protects retinal ganglion cells in a preclinical model of retinal ischemia/reperfusion injury and stabilizes visual field in diabetic patients with glaucoma
  4. Topical WIN 55,212-2 Confers Long-Term Intraocular-Pressure-Independent Neuroprotection in the DBA/2J Mouse Model of Glaucoma
  5. Comparing eptinezumab with onabotulinumtoxinA in the treatment of chronic migraine: a real-world evidence study
  6. Pharmacoutilization data-driven AI-assisted diagnosis algorithm to improve the pharmacological treatment of pain and agitation in patients suffering from severe dementia
  7. Efficacy and safety of mAbs anti-CGRP/CGRP R (eptinezumab and erenumab) or atogepant in combination with onabotulinumtoxinA in refractory chronic migraine: a clinical trial protocol
  8. Multi-center Translational Trial of Remote Ischemic Conditioning in Acute Ischemic Stroke (TRICS BASIC)
  9. Clinical and Market Analysis of NanoBEO: A Public-Worth, Innovative Therapy for Behavioral and Psychological Symptoms of Dementia (BPSD)—Emerging Evidence and Its Implications for a Health Technology Assessment (HTA) and Decision-Making in National Hea...
  10. The Antidepressant Drug Amitriptyline Affects Human SH-SY5Y Neuroblastoma Cell Proliferation and Modulates Autophagy
  11. Brain Ischemic Tolerance Triggered by Preconditioning Involves Modulation of Tumor Necrosis Factor-α-Stimulated Gene 6 (TSG-6) in Mice Subjected to Transient Middle Cerebral Artery Occlusion
  12. Efficacy of therapeutic intervention with NanoBEO to manage agitation and pain in patients suffering from severe dementia: a pilot clinical trial
  13. Hericenone C attenuates the second phase of formalin-induced nociceptive behavior by suppressing the accumulation of CD11c-positive cells in the paw epidermis via phosphorylated P65
  14. Basic, Translational, and Clinical Research on Dementia
  15. Role of Spinal Cholecystokinin Octapeptide, Nociceptin/Orphanin FQ, and Hemokinin-1 in Diabetic Allodynia
  16. Motor behavior induced by bergamot essential oil in experimental tasks is differentially modulated by pretreatment with metabotropic glutamate receptor 2/3 or 5 antagonists
  17. Epigenetic and nanotechnology alliance to fight stroke-induced brain damage
  18. Zeaxanthin exerts anti-inflammatory effects in vitro and provides significant neuroprotection in mice subjected to transient middle cerebral artery occlusion
  19. Exploitation of Autophagy Inducers in the Management of Dementia: A Systematic Review
  20. Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establi...
  21. Decoding metabolic signatures in Alzheimer’s disease: a mitochondrial perspective
  22. Effect of genotype on individual response to the pharmacological treatment of glaucoma: a systematic review and meta-analysis
  23. Scopolamine-Induced Memory Impairment in Mice: Effects of PEA-OXA on Memory Retrieval and Hippocampal LTP
  24. Neuroprotective Effect of a Nutritional Supplement Containing Spearmint Extract, Forskolin, Homotaurine and Group B Vitamins in a Mouse Model of Transient Ocular Hypertension
  25. Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
  26. Efficacy of Essential Oils in Relieving Cancer Pain: A Systematic Review and Meta-Analysis
  27. Characterization of the Involvement of Tumour Necrosis Factor (TNF)-α-Stimulated Gene 6 (TSG-6) in Ischemic Brain Injury Caused by Middle Cerebral Artery Occlusion in Mouse
  28. Harmonization of sensorimotor deficit assessment in a registered multicentre pre-clinical randomized controlled trial using two models of ischemic stroke
  29. Tumor Necrosis Factor (TNF)-α-Stimulated Gene 6 (TSG-6): A Promising Immunomodulatory Target in Acute Neurodegenerative Diseases
  30. 2-pentadecyl-2-oxazoline prevents cognitive and social behaviour impairments in the Amyloid β-induced Alzheimer-like mice model: Bring the α2 adrenergic receptor back into play
  31. Focus On Zavegepant: The First Intranasal Third-Generation Gepant
  32. NAbiximols Clinical Translation To the treatment of Pain and Agitation In Severe Dementia (NACTOPAISD): Clinical trial protocol
  33. Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence
  34. Analgesic Characteristics of NanoBEO Released by an Airless Dispenser for the Control of Agitation in Severe Dementia
  35. Transgenic Mice for the Translational Study of Neuropathic Pain and Dystonia
  36. Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine
  37. Dementia therapeutics and cognitive rehabilitation
  38. Pharmacotechnological Advances for Clinical Translation of Essential Oils for the Treatment of Pain and Agitation in Severe Dementia
  39. Targeting Neuroplasticity for the Management of Pain and Agitation in Alzheimer’s Disease via Bergamot Nanotherapy
  40. Homo-AMPA in the periaqueductal grey modulates pain and rostral ventromedial medulla activity in diabetic neuropathic mice
  41. Requirements for Translation in Clinical Trials of Aromatherapy: The Case of the Essential Oil of Bergamot (BEO) for Management of Agitation in Severe Dementia
  42. CB1R, CB2R and TRPV1 expression and modulation in in vivo, animal glaucoma models: A systematic review
  43. Pain and agitation treatment in severe dementia patients: The need for Italian Mobilization–Observation–Behavior–Intensity–Dementia (I-MOBID2) pain scale translation, adaptation and validation with psychometric testing
  44. Translational Value of the Transdermal Administration of Bergamot Essential Oil and of Its Fractions
  45. PEA-OXA ameliorates allodynia, neuropsychiatric and adipose tissue remodeling induced by social isolation
  46. Pharmacological Treatment of Pain and Agitation in Severe Dementia and Responsiveness to Change of the Italian Mobilization–Observation–Behavior–Intensity–Dementia (I-MOBID2) Pain Scale: Study Protocol
  47. Antispasmodic Effect of Bergamot Essential Oil on Rat Isolated Gut Tissues
  48. Ischemic Preconditioning Modulates the Peripheral Innate Immune System to Promote Anti-Inflammatory and Protective Responses in Mice Subjected to Focal Cerebral Ischemia
  49. Real world considerations for newly approved CGRP receptor antagonists in migraine care
  50. ROBOCOP (ROBOtic Care of Poststroke Pain): Study Protocol for a Randomized Trial to Assess Robot-Assisted Functional and Motor Recovery and Impact on Poststroke Pain Development
  51. Dementia and COVID-19: A Case Report and Literature Review on Pain Management
  52. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence
  53. Preclinical Characterization of Antinociceptive Effect of Bergamot Essential Oil and of Its Fractions for Rational Translation in Complementary Therapy
  54. Aromatherapy in Stroke Patients: Is it Time to Begin?
  55. New trends in pharmacological control of neuropsychiatric symptoms of dementia
  56. Exploitation of Thermal Sensitivity and Hyperalgesia in a Mouse Model of Dystonia
  57. Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab
  58. Bergamot rehabilitation AgaINst agitation in dementia (BRAINAID): Study protocol for a randomized, double‐blind, placebo‐controlled trial to assess the efficacy of furocoumarin‐free bergamot loaded in a nanotechnology‐based delive...
  59. Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
  60. Editorial: “Novel Pain Therapeutics: From Basic Research to Clinical Translation and Rehabilitation”
  61. Systemic administration of sunflower oil exerts neuroprotection in a mouse model of transient focal cerebral ischaemia
  62. Development and Translation of NanoBEO, a Nanotechnology-Based Delivery System of Bergamot Essential Oil Deprived of Furocumarins, in the Control of Agitation in Severe Dementia
  63. Efficacy of Essential Oils in Pain: A Systematic Review and Meta-Analysis of Preclinical Evidence
  64. Effect of Gabapentin in a Neuropathic Pain Model in Mice Overexpressing Human Wild-Type or Human Mutated Torsin A
  65. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
  66. Opioids in Post-stroke Pain: A Systematic Review and Meta-Analysis
  67. Multicentre translational Trial of Remote Ischaemic Conditioning in Acute Ischaemic Stroke (TRICS): protocol of multicentre, parallel group, randomised, preclinical trial in female and male rat and mouse from the Italian Stroke Organization (ISO) Basic...
  68. Contribution of Histamine to Nociceptive Behaviors Induced by Intrathecally Administered Cholecystokinin-8
  69. Natural Products: Evidence for Neuroprotection to Be Exploited in Glaucoma
  70. Pattern of treatment of behavioural and psychological symptoms of dementia and pain: evidence on pharmacoutilization from a large real-world sample and from a centre for cognitive disturbances and dementia
  71. Effects of the autophagy modulators d-limonene and chloroquine on vimentin levels in SH-SY5Y cells
  72. Pain Assessment and Treatment in Dementia at the Time of Coronavirus Disease COVID-19
  73. Behavioral Effects of Continuously Administered Bergamot Essential Oil on Mice With Partial Sciatic Nerve Ligation
  74. Modulation of Cerebral Store-operated Calcium Entry-regulatory Factor (SARAF) and Peripheral Orai1 Following Focal Cerebral Ischemia and Preconditioning in Mice
  75. Pharmacokinetic Interactions between Herbal Medicines and Drugs: Their Mechanisms and Clinical Relevance
  76. Effects of Aging on Formalin-Induced Pain Behavior and Analgesic Activity of Gabapentin in C57BL/6 Mice
  77. Role of 5-HT1A Receptor in the Anxiolytic-Relaxant Effects of Bergamot Essential Oil in Rodent
  78. The Role of Autophagy in Glaucomatous Optic Neuropathy
  79. Pattern of triptans use: a retrospective prescription study in Calabria, Italy
  80. Brain networks reorganization and functional disability in glaucoma
  81. Effects of caloric restriction on retinal aging and neurodegeneration
  82. Evidence on the neuroprotective properties of brimonidine in glaucoma
  83. Impact of nutraceuticals on glaucoma: A systematic review
  84. Preface
  85. Preface
  86. Azithromycin Affords Neuroprotection in Rat Undergone Transient Focal Cerebral Ischemia
  87. Aging Brain: In Search of Better Neurotherapeutics
  88. Neuropharmacological Properties of the Essential Oil of Bergamot for the Clinical Management of Pain-Related BPSDs
  89. Anxiolytic-Like Effects of Bergamot Essential Oil Are Insensitive to Flumazenil in Rats
  90. Neuropharmacology of the Neuropsychiatric Symptoms of Dementia and Role of Pain: Essential Oil of Bergamot as a Novel Therapeutic Approach
  91. New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
  92. The tricyclic antidepressant clomipramine inhibits neuronal autophagic flux
  93. Diabetic retinopathy and age-related macular degeneration: a survey of pharmacoutilization and cost in Calabria, Italy
  94. Eptinezumab for the treatment of migraine
  95. Possible involvement of the peripheral Mu-opioid system in antinociception induced by bergamot essential oil to allodynia after peripheral nerve injury
  96. Rapamycin and fasting sustain autophagy response activated by ischemia/reperfusion injury and promote retinal ganglion cell survival
  97. Antinociceptive effect of inhalation of the essential oil of bergamot in mice
  98. Glaucoma and Alzheimer Disease: One Age-Related Neurodegenerative Disease of the Brain
  99. Glaucoma: In Search of Better Neurotherapeutics
  100. Paradigm Shift to Neuroimmunomodulation for Translational Neuroprotection in Stroke
  101. On the Role of Store-Operated Calcium Entry in Acute and Chronic Neurodegenerative Diseases
  102. Neuroprotective agents in the management of glaucoma
  103. Early LC3 lipidation induced by d -limonene does not rely on mTOR inhibition, ERK activation and ROS production and it is associated with reduced clonogenic capacity of SH-SY5Y neuroblastoma cells
  104. Evidence for accuracy of pain assessment and painkillers utilization in neuropsychiatric symptoms of dementia in Calabria region, Italy
  105. Excitatory and inhibitory amino acid neurotransmitters in stroke: from neurotoxicity to ischemic tolerance
  106. Bergamot Essential Oil Attenuates Anxiety-Like Behaviour in Rats
  107. Opioids Resistance in Chronic Pain Management
  108. Aromatherapy and Aromatic Plants for the Treatment of Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: Clinical Evidence and Possible Mechanisms
  109. The need for better access to pain treatment: learning from drug consumption trends in the USA
  110. Poly(ADP-ribose) polymerase is not involved in the neuroprotection exerted by azithromycin against ischemic stroke in mice
  111. Retinal ganglion cell death in glaucoma: Exploring the role of neuroinflammation
  112. New strategies for neuroprotection in glaucoma, a disease that affects the central nervous system
  113. Neuroprotective Properties of a Macrolide Antibiotic in a Mouse Model of Middle Cerebral Artery Occlusion: Characterization of the Immunomodulatory Effects and Validation of the Efficacy of Intravenous Administration
  114. Involvement of spinal glutamate in nociceptive behavior induced by intrathecal administration of hemokinin-1 in mice
  115. Drug repurposing for immune modulation in acute ischemic stroke
  116. Azithromycin protects mice against ischemic stroke injury by promoting macrophage transition towards M2 phenotype
  117. Activation of RXR/PPARγ underlies neuroprotection by bexarotene in ischemic stroke
  118. Aromatherapy
  119. Rational modulation of the innate immune system for neuroprotection in ischemic stroke
  120. Links among glaucoma, neurodegenerative, and vascular diseases of the central nervous system
  121. Natural compounds and retinal ganglion cell neuroprotection
  122. Autophagy dysregulation and the fate of retinal ganglion cells in glaucomatous optic neuropathy
  123. Drug repurposing and beyond: the fundamental role of pharmacology
  124. Effect of plantar subcutaneous administration of bergamot essential oil and linalool on formalin-induced nociceptive behavior in mice
  125. Exploitation of Cytotoxicity of Some Essential Oils for Translation in Cancer Therapy
  126. Preface: New Trends in Basic and Clinical Research of Glaucoma: A Neurodegenerative Disease of the Visual System Part A
  127. Preface: New Trends in Basic and Clinical Research of Glaucoma:A Neurodegenerative Disease of the Visual System Part B
  128. Spinal Autophagy is Differently Modulated in Distinct Mouse Models of Neuropathic Pain
  129. Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia
  130. Role of D-Limonene in Autophagy Induced by Bergamot Essential Oil in SH-SY5Y Neuroblastoma Cells
  131. Early reperfusion injury is associated to MMP2 and IL-1β elevation in cortical neurons of rats subjected to middle cerebral artery occlusion
  132. Inflammation in stroke
  133. The Essential Oil of Bergamot Stimulates Reactive Oxygen Species Production in Human Polymorphonuclear Leukocytes
  134. Implication of limonene and linalyl acetate in cytotoxicity induced by bergamot essential oil in human neuroblastoma cells
  135. Impairment of Neuronal Glutamate Uptake and Modulation of the Glutamate Transporter GLT-1 Induced by Retinal Ischemia
  136. In search of new targets for retinal neuroprotection: is there a role for autophagy?
  137. Brain involvement in glaucoma: advanced neuroimaging for understanding and monitoring a new target for therapy
  138. Peripherally injected linalool and bergamot essential oil attenuate mechanical allodynia via inhibiting spinal ERK phosphorylation
  139. Involvement of peripheral cannabinoid and opioid receptors in β-caryophyllene-induced antinociception
  140. The involvement of the spinal release of glutamate and nitric oxide in peripheral noxious stimulation-induced pain-related behaviors—Study in mouse spinal microdialysis
  141. Death in pain: peripheral nerve injury and spinal neurodegenerative mechanisms
  142. Understanding anomalous adaptation in chronic pain for successful development of disease modifying drugs
  143. Neuroprotection by leptin in a rat model of permanent cerebral ischemia: effects on STAT3 phosphorylation in discrete cells of the brain
  144. Calpain-mediated cleavage of Beclin-1 and autophagy deregulation following retinal ischemic injury in vivo
  145. IkappaB-alpha expression following transient focal cerebral ischemia is modulated by nitric oxide
  146. Dermorphin tetrapeptide analogs as potent and long-lasting analgesics with pharmacological profiles distinct from morphine
  147. Autophagy impairment in a mouse model of neuropathic pain
  148. Intraplantar injection of bergamot essential oil induces peripheral antinociception mediated by opioid mechanism
  149. Neuropharmacology of the essential oil of bergamot
  150. Identification of distinct cellular pools of interleukin-1β during the evolution of the neuroinflammatory response induced by transient middle cerebral artery occlusion in the brain of rat
  151. Alterations of the endocannabinoid system in an animal model of migraine: Evaluation in cerebral areas of rat
  152. Cell signaling pathways in the mechanisms of neuroprotection afforded by bergamot essential oil against NMDA-induced cell death in vitro
  153. Chapter 28 Identification of Novel Pharmacological Targets to Minimize Excitotoxic Retinal Damage
  154. Chapter 25 Oxidative Stress in Stroke Pathophysiology
  155. Chapter 27 Prevention of Glutamate Accumulation and Upregulation of Phospho‐Akt may Account for Neuroprotection Afforded by Bergamot Essential Oil against Brain Injury Induced by Focal Cerebral Ischemia in Rat
  156. Chapter 17 (–)‐Linalool Attenuates Allodynia in Neuropathic Pain Induced by Spinal Nerve Ligation in C57/Bl6 Mice
  157. Preface
  158. Chapter 18 Intraplantar Injection Of Bergamot Essential Oil Into The Mouse Hindpaw
  159. Post-ischemic brain damage: pathophysiology and role of inflammatory mediators
  160. Post-ischemic brain damage: in search of novel neurotherapeutics
  161. Post-ischemic brain damage: the endocannabinoid system in the mechanisms of neuronal death
  162. Modulation of pro-survival and death-associated pathways under retinal ischemia/reperfusion: effects of NMDA receptor blockade
  163. Exploitation of the HIV-1 coat glycoprotein, gp120, in neurodegenerative studies in vivo
  164. Brain regional and cellular localization of gelatinase activity in rat that have undergone transient middle cerebral artery occlusion
  165. Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
  166. 17β-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
  167. Preface
  168. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
  169. Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17β-estradiol
  170. Involvement of the Endocannabinoid System in Retinal Damage after High Intraocular Pressure–Induced Ischemia in Rats
  171. Identification of Transglutaminase 3 Splicing Isoforms
  172. Extracellular signal-regulated kinase (ERK) and nitric oxide synthase mediate intrathecal morphine-induced nociceptive behavior
  173. The essential oil of bergamot enhances the levels of amino acid neurotransmitters in the hippocampus of rat: Implication of monoterpene hydrocarbons
  174. Neuroinflammation in neuronal degeneration and repair
  175. Early Upregulation of Matrix Metalloproteinases Following Reperfusion Triggers Neuroinflammatory Mediators in Brain Ischemia in Rat
  176. Evidence to Implicate Early Modulation of Interleukin‐1β Expression in the Neuroprotection Afforded by 17β‐Estradiol in Male Rats Undergone Transient Middle Cerebral Artery Occlusion
  177. Evidence Implicating Matrix Metalloproteinases in the Mechanism Underlying Accumulation of IL‐1β and Neuronal Apoptosis in the Neocortex of HIV/gp120‐Exposed Rats
  178. Neuroprotective Effect of Nitroglycerin in a Rodent Model of Ischemic Stroke: Evaluation of Bcl‐2 Expression
  179. Preface
  180. Retinal Damage Caused by High Intraocular Pressure–Induced Transient Ischemia is Prevented by Coenzyme Q10 in Rat
  181. Evidence that Nitric Oxide Is Involved in the Control of Electrocortical Arousal
  182. Outcomes of a pharmacoepidemiological survey on the antibiotic treatment of uncomplicated acute cystitis in community☆
  183. The crucial role of neuronal plasticity in pain and cell death
  184. 17β-Estradiol Protects SH-SY5Y Cells Against HIV-1 gp120-Induced Cell Death: Evidence for a Role of Estrogen Receptors
  185. Editorial
  186. 17β-Estradiol Reduces Neuronal Apoptosis Induced by HIV-1 gp120 in the Neocortex of Rat
  187. Neurochemical Evidence to Implicate Elevated Glutamate in the Mechanisms of High Intraocular Pressure (IOP)-induced Retinal Ganglion Cell Death in Rat
  188. From clinical evidence to molecular mechanisms underlying neuroprotection afforded by estrogens
  189. Neuroprotection by the caspase-1 inhibitor Ac-YVAD-(acyloxy)mk in experimental neuroAIDS is independent from IL-1β generation
  190. Estradiol reduces cytochrome c translocation and minimizes hippocampal damage caused by transient global ischemia in rat
  191. Transglutaminase 5 is acetylated at the N-terminal end
  192. Enhanced anandamide degradation is associated with neuronal apoptosis induced by the HIV-1 coat glycoprotein gp120 in the rat neocortex
  193. p73-alpha is capable of inducing scotin and ER stress
  194. A Novel Recessive Connexin 31 (GJB3) Mutation in a Case of Erythrokeratodermia Variabilis
  195. Involvement of a Glutamatergic Mechanism in δ-Dendrotoxin-Induced Hippocampal Neuronal Cell Loss in the Rat
  196. Inducible nitric oxide synthase is involved in the mechanisms of cocaine enhanced neuronal apoptosis induced by HIV-1 gp120 in theneocortex of rat
  197. Neurobiological mediators of neuronal apoptosis in experimental neuroAIDS
  198. Apoptosis in the Mechanisms of Neuronal Plasticity in the Developing Visual System
  199. Calabria: sun, sand, and cell death
  200. Excitotoxic Mechanisms of Apoptosis in the Mammalian Visual System Following Monocular Visual Deprivation
  201. Cholesterol-dependent modulation of the toxicity of HIV-1 coat protein gp120 in human neuroblastoma cells
  202. Abnormal Expression of Neuronal Nitric Oxide Synthase Triggers Limbic Seizures and Hippocampal Damage in Rat
  203. HIV-1 Coat Glycoprotein gp120 Induces Apoptosis in Rat Brain Neocortex by Deranging the Arachidonate Cascade in Favor of Prostanoids
  204. HIV-1 coat protein gp120 stimulates interleukin-1β secretion from human neuroblastoma cells: evidence for a role in the mechanism of cell death
  205. Evidence that the HIV-1 coat protein gp120 causes neuronal apoptosis in the neocortex of rat via a mechanism involving CXCR4 chemokine receptor
  206. Functional role of inducible nitric oxide synthase on mouse colonic motility
  207. Evidence that increases of mitochondrial immunoreactive IL-1β by HIV-1 gp120 implicatein situcleavage of pro-IL-1β in the neocortex of rat
  208. CXCR4-activated astrocyte glutamate release via TNFα: amplification by microglia triggers neurotoxicity
  209. Apoptosis in the Dorsal Lateral Geniculate Nucleus after Monocular Deprivation Involves Glutamate Signaling, NO Production, and PARP Activation
  210. Effects of α-dendrotoxin and dendrotoxin K on extracellular excitatory amino acids and on electroencephalograph spectral power in the hippocampus of anaesthetised rats
  211. Apoptosis Induced by gp120 in the Neocortex of Rat Involves Enhanced Expression of Cyclooxygenase Type 2 and Is Prevented by NMDA Receptor Antagonists and by the 21-Aminosteroid U-74389G
  212. Systemic administration of cocaine, given alone or in combination with sensory stimuli, differentially affects l-arginine-nitric oxide metabolism in discrete regions of the brain of rat
  213. Involvement of interleukin-1β in the mechanism of human immunodeficiency virus type 1 (HIV-1) recombinant protein gp120-induced apoptosis in the neocortex of rat
  214. Conference
  215. Paraquat: A Useful Tool for thein vivoStudy of Mechanisms of Neuronal Cell Death
  216. The HIV Envelope Protein gp120 in the Nervous System
  217. Intrahippocampal injection of paraquat produces apoptotic cell death which is prevented by the lazaroid U74389G, in rats
  218. HIV-1 gp120-Induced Apoptosis in the Rat Neocortex Involves Enhanced Expression of Cyclo-oxygenase Type 2 (COX-2)
  219. Systemic Administration of Nω-Nitro-l-Arginine Methyl Ester and Indomethacin Reduces the Elevation of Brain PGE2Content and Prevents Seizures and Hippocampal Damage Evoked by LiCl and Tacrine in Rat
  220. The effect of hydroxylation of linoleoyl amides on their cannabinomimetic properties
  221. Seizures and Hippocampal Damage Produced by Dendrotoxin-K in Rats Is Prevented by the 21-Aminosteroid U-74389G
  222. N-Methyl-d-aspartate (NMDA) and non-NMDA glutamate receptor antagonists protect from apoptosis induced in the lateral geniculate nucleus of rabbits exposed to the dark
  223. Conference
  224. The human immunodeficiency virus type 1 (HIV-1) glycoprotein gp120 reduces the expression of neuronal nitric oxide synthase in the hippocampus but not in the cerebral cortex and medial septal nucleus of rat
  225. Nω-nitro-L-arginine methyl ester prevents apoptosis induced in the lateral geniculate nucleus by light deprivation in adult rabbit
  226. N-methyl-d-aspartate and nonn-methyl-d-aspartate receptors mediate seizures and CA1 hippocampal damage induced by dendrotoxin-K in rats
  227. Intracerebral injection of human immunodeficiency virus type 1 coat protein gp120 differentially affects the expression of nerve growth factor and nitric oxide synthase in the hippocampus of rat.
  228. Systemic administration of lithium chloride and tacrine but not kainic acid augments citrulline content of rat brain
  229. Possible modulation of auditory middle latency responses by nitric oxide in the inferior colliculus of anaesthetized rats
  230. HIV-1 gp120 Produces DNA Fragmentation in the Cerebral Cortex of Rat
  231. Lack of Involvement of Nitric Oxide in the Mechanisms of Seizures and Hippocampal Damage Produced by Kainate and Ouabain in Rats
  232. Does the HIV-1 coat protein gp120 produce brain damage?
  233. Intracerebral injection of human immunodeficiency virus type 1 coat glycoprotein GP120 does not produce neurodegeneration in rats
  234. Neurodegeneration Produced by Intrahippocampal Injection of Paraquat is Reduced by Systemic Administration of the 21-Aminosteroid U74389F in Rats
  235. Hippocampal damage produced in rats by α-dendrotoxin—a selective K+ channel blocker—involves non-NMDA receptor activation
  236. Tetanus toxin as a neurobiological tool to study mechanisms of neuronal cell death in the mammalian brain
  237. Lithium and Tacrine Increase the Expression of Nitric Oxide Synthase mRNA in the Hippocampus of Rat
  238. Persistent muscarinic excitation in guinea-pig olfactory cortex neurons: Involvement of a slow post-stimulus afterdepolarizing current
  239. HIV gp120 Glycoprotein Stimulates the Inducible Isoform of NO Synthase in Human Cultured Astrocytoma Cells
  240. Systemic administration of lithium chloride and tacrine increases nitric oxide synthase activity in the hippocampus of rats
  241. Inhibition by Nω-nitro-L-arginine methyl ester of the electrocortical arousal response in rats
  242. Antagonists of N-methyl-D-aspartate receptors block seizures induced by putrescine in the deep prepiriform cortex
  243. Altered Sensitivity of ?2-Adrenoceptors in the Brain during Aging in Rats
  244. Glutamate transmission is involved in the mechanisms of neuronal degeneration produced by intrahippocampal tetanus toxin in rats
  245. Production of Limbic Motor Seizures and Brain Damage by Systemic and Intracerebral Injections of Paraquat in Rats
  246. Neurotoxic Effects Induced by Intracerebral and Systemic Injection of Paraquat in Rats
  247. Metabotropic (glutamate) receptor agonists induce a post-stimulus afterdepolarization in guinea-pig olfactory cortex neurones in vitro
  248. Role of nitric oxide in the pathophysiology of epilepsy and brain damage in rats
  249. Production of seizures and brain damage in rats by α-dendrotoxin, a selective K+ channel blocker
  250. Tacrine-induced seizures and brain damage in LiCl-treated rats can be prevented by Nω-nitro-L-arginine methyl ester
  251. Epileptogenic effects of skin extracts from the Australian frog Pseudophryne coriacea after intracerebral microinfusion in rats
  252. Muscarinic receptor activation induces a prolonged post-stimulus afterdepolarization with a conductance decrease in guinea-pig olfactory cortex neurones in vitro
  253. High vulnerability of dentate granule cells to the neuropathological effects induced by intrahippocampal injection of tetanus toxin
  254. Muscarinic inhibition of excitatory neurotransmission in guinea-pig olfactory cortex slices: Weak antagonism by M3-muscarinic receptor antagonists
  255. Hippocampal damage produced by tetanus toxin in rats can be prevented by lesioning CA1 pyramidal cell excitatory afferents
  256. Characteristics of tetanus toxin and its exploitation in neurodegenerative studies
  257. Prevention by the NMDA receptor antagonist, MK801 of neuronal loss produced by tetanus toxin in the rat hippocampus
  258. Different profile of electrocortical power spectrum changes after micro-infusion into the locus coeruleus of selective agonists at various opioid receptor subtypes in rats
  259. Carbachol-induced suppression of the surface N-wave in guinea-pig olfactory cortex slices: Weak antagonism by M3-selective muscarinic antagonists, HHSiD and p-F-HHSiD
  260. Behavioural and neuropathological effects produced by tetanus toxin injected into the hippocampus of rats
  261. Hippocampal damage produced by tetanus toxin in rats can be prevented by lesioning excitatory afferents to CA1 pyramidal cell layer
  262. Muscarinic suppression of the evoked N-wave by oxotremorine-M-recorded in the guinea-pig olfactory cortex slice
  263. Tetanus toxin produces neuronal loss and a reduction in GABAA but not GABAB binding sites in rat hippocampus
  264. Age-dependent ECoG spectrum power alterations are reduced by phosphatidylserine in rats
  265. Inhibition by pertussis toxin of the soporific effects induced by stimulation of dopamine D2, autoreceptors in the ventral tegmental area in rats
  266. Effects of pertussis toxin on the behavioural and ECoG spectrum changes induced by clonidine and yohimbine after their microinfusion into the locus coeruleus
  267. Microinfusion of clonidine and yohimbine into locus coeruleus alters EEG power spectrum: effects of aging and reversal by phosphatidylserine
  268. Dopamine D-2 receptors in the ventral tegmental area mediate behavioural and electrocortical sleep of dopaminergic drugs in rats
  269. Ventral tegmental area: site through which dopamine D2-receptor agonists evoke behavioural and electrocortical sleep in rats
  270. Behavioural and ECoG spectrum power effects after intraventricular injection of drugs altering dopaminergic transmission in rats
  271. Behavioural and electrocortical changes induced by muscimol in rats withdrawn from chronic treatment with diazepam
  272. Behavioural and electrocortical spectrum power effects of growth hormone releasing factor in rats
  273. Electrocortical spectrum power effects of different classes of neuroleptics in rats
  274. Behavioural and spectrum power effects of opioid peptides in chicks
  275. Behavioural and Electrocortical Spectrum Power Changes After Intraventricular Injection of Patulin in Rats
  276. Evidence that behavioural and electrocortical sleep induced by guanfacine is due to stimulation of α2-adrenoceptors